Axonics® to Host Presentation of Full 2-Year Clinical Results from ARTISAN-SNM Pivotal Study on September 9

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will host a webinar on September 9 during which principal investigators of the ARTISAN-SNM pivotal study will present full 2-year clinical results. Axonics previously announced topline results of the study at 2-years, which demonstrat

Click to view original post